References
- Ardizzone S, Porro GB. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253–86
- Assadulah K, Sterry W, Volk HD. Interleukine-10 therapy–review of new approach. Pharmacol Rev 2003; 55: 241–69
- Barada KA, Mourad FH, Sawah SI, Khoury C, Safieh-Garabedian B, Nassar CF, Tawil A, Jurjus A, Saadé NE. Up-regulation of nerve growth factor and interleukin-10 in inflamed and non-inflamed intestinal segments in rats with experimental colitis. Cytokine 2007; 37: 236–45
- Bogataj M, Mrhar A, Lavrič A, Černe M, Tibaut D, Štalc A, Urleb U, Mateovič T, Cof G, Kerč J, et al. Gastroresistant pharmaceutical dosage form comprinsing N-(2-(2-phthalimidoethoxy-)acetyl)-L-alanyl-D-glutamic acid (LK-423). Published International Application WO 2005/092295 A1, 2005, 6 October.
- Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin Biol Ther 2003; 3: 725–31
- De Waal Malefyt R. 2001. IL-10. In: Oppenheim JJ, Feldmann M, eds. Cytokine Reference. Academic Press, Elsevier, Vol 1, 165–86
- Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, Eigler A, Lehr HA, Endres S. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000; 292: 22–30
- Kühn R, Löhler J, Rennick D, Rajewski K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263–74
- Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004; 10: 620–5
- Lindsay JO, Hodgson HJF. The immunoregulatory cytokine interleukin-10–a therapy for Crohn's disease?. Aliment Pharmacol Ther 2001; 15: 1709–16
- Moriguchi M, Urabe K, Norisada N, Ochi C, Štalc A, Urleb U, Muraoka S. Therapeutic effect of LK 423, a phthalimido-desmuramyl-dipeptide compound, on dextran sulfate sodium-induced colitis in rodents through restoring their interleukin-10 producing capacity. Arzneim-Forsch/Drug Res 1999; 49: 184–92
- Moore KW, De Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukine-10 receptor. Annu Rev Immunol 2001; 19: 683–765
- Nasake H, Okazaki K, Tabata Y, Ozeki M, Watanabe N, Ohana M, Uose S, Uchida K, Nishi T, Mastuura M, et al. New cytokine delivery system using gelatine microspheres containing interleukine-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther 2002; 301: 59–65
- Ochi C, Norisada N, Moriguchi M, Štalc A, Urleb U, Muraoka S. Interleukin-10 inducing activity of LK423, a phthalimido-desmuramyldipepdide compound. Arzneim-Forsch/Drug Res 1999; 49: 71–9
- Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22: 382–89
- Smrdel P, Bogataj M, Mrhar A. Comparison of gastrointestinal conditions of human and laboratory animals from the colon delivery viewpoint. Pharm J Slovenia 2006a; 57: 298–304
- Smrdel P, Bogataj M, Podlogar F, Planinšek O, Zajc N, Mazaj M, Kaučič V, Mrhar A. Characterisation of calcium alginate beads containing structurally similar drugs. Drug Dev Ind Pharm 2006b; 32: 623–33
- Smrdel P, Bogataj M, Zega A, Planinšek O, Mrhar M. Shape optimization and characterisation of polysaccharide beads prepared by ionotropic gelation. J Microencapsul 2008; 25: 90–105
- Smrdel P, Grabnar I, Locatelli I, Černe M, Andrenšek S, Kovačič N, Kristl A, Bogataj M, Urleb U, Mrhar M. Physicochemical and preclinical pharmacokinetic and toxicological evaluation of LK-423–a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity. Drug Dev Ind Pharm 2009; 35: 1293–304
- Steidler L, Hans W, Schotte L, Neirynck S, Obermeir F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352–5
- Strober W, Fuss IJ. Experimental models of mucosal inflammation. Adv Exp Med Biol 2006; 579: 55–97
- Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514–21
- Urleb U, Krbavčič A, Sollner M, Kikelj D, Pečar S. Synthesis of phthalimido-desmuramylpeptide analogues as potential immunomodulating agents. Arch Pharm 1995; 328: 113–7
- Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine?. Eur Cytokine Netw 2000; 11: 153–60
- Yoneda F, Muraoka S, Moriguchi M, Norisada N, Ochi C, Štalc A, Lavrič A, Urleb U. Anti-inflammatory medicinal compositions. Published International Application WO 0135982 A1, 2001, 25 May.